In a controlled clinical study, 30 adult patients (16 females, 14 males, mean age 46.0 +/- 7.6, mean body weight 69.4 +/- 10.2 kg) with mild-moderate essential hypertension were treated with ketanserin (20 mg twice daily) or metoprolol (100 mg daily) for the first month and 40 mg twice daily or 100 mg twice daily during the second month. Results showed antihypertensive efficacy and systemic tolerability of ketanserin to be equal to that of metoprolol and better cardiac tolerance for ketanserin.

Download full-text PDF

Source

Publication Analysis

Top Keywords

100 daily
8
[ketanserin metoprolol
4
metoprolol treatment
4
treatment essential
4
essential hypertension]
4
hypertension] controlled
4
controlled clinical
4
clinical study
4
study adult
4
adult patients
4

Similar Publications

Introduction: Recovery community centers (RCCs) offer various support services to people in addiction recovery, such as hosting mutual help meetings and sober social activities and providing employment support and recovery coaching. To date, very little is known about RCCs and their relationship with recovery outcomes, as well as how RCCs may vary in helpfulness from visit to visit. This study used a daily diary approach to assess the intraindividual variation of daily RCC helpfulness, and whether RCC helpfulness predicted the holistic recovery indices of daily meaningfulness and recovery identity.

View Article and Find Full Text PDF

Introduction: This study examines the effects of steam-flaked corn starter on pre-weaned Simmental calves' growth, immunity, and metabolism. Despite benefits shown in adult cattle, research on calves is limited. The goal is to optimize calf feeding for better growth, health, and nutrient use.

View Article and Find Full Text PDF

Optimal timing for lithium levels.

F1000Res

January 2025

Departments of Psychiatry, Neurology, Radiology, and Neuroscience, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.

Reddy and Reddy (2014) discuss the optimal timing for lithium levels in patients taking once-daily extended-release lithium formulations. They argue for blood sampling 24 h after the previous dose rather than the standard 12 h. I interpret the data quite differently.

View Article and Find Full Text PDF

Spaced Transcranial Direct Current Stimulation for Major Depression.

Am J Psychiatry

January 2025

Centre Hospitalier de l'Université de Montréal (CHUM) and Centre de Recherche du CHUM (CRCHUM), University of Montreal, Montreal (Couture, Desbeaumes Jodoin, Bousseau, Sarshoghi, Miron, Lespérance); IfADo Leibniz Research Center for Working Environment and Human Factors at TU Dortmund, Germany, and Bielefeld University, University Hospital OWL, Protestant Hospital of Bethel Foundation, University Clinic of Psychiatry and Psychotherapy, and German Center for Mental Health (Nitsche); Temerty Centre for Therapeutic Brain Intervention and Campbell Family Research Institute, Centre for Addiction and Mental Health (CAMH) and Department of Psychiatry, University of Toronto, Toronto (Blumberger); Department of Medicine (Bolduc) and Department of Psychiatry and Addictology (Lespérance, Miron), Faculty of Medicine, University of Montreal, Montreal; Interventional Psychiatry Program, Department of Psychiatry, UC San Diego School of Medicine, San Diego (Weissman, Appelbaum, Daskalakis, Poorganji, Miron).

Objective: This study investigated spaced transcranial direct current stimulation for major depressive disorder, focusing on feasibility.

Methods: In a prospective open-label study, 30 participants with major depressive disorder were enrolled to receive a 50-session transcranial direct current stimulation (tDCS) treatment over 2 weeks. The feasibility, safety, tolerability, and preliminary therapeutic effects of this tDCS protocol were assessed using the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline and 1-week and 4-week follow-ups, as well as with the 6-item HAM-D (HAM-D-6) daily during treatment.

View Article and Find Full Text PDF

Background: The retinal degenerative diseases retinitis pigmentosa (RP) and atrophic age- related macular degeneration (AMD) are characterized by vision loss from photoreceptor (PR) degeneration. Unfortunately, current treatments for these diseases are limited at best. Genetic and other preclinical evidence suggest a relationship between retinal degeneration and inflammation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!